Aptevo Therapeutics Reports 2026 Annual Meeting Voting Results

What Happened
Aptevo Therapeutics, Inc. (APVO) filed an 8-K reporting the results of its Annual Meeting of Stockholders held on August 21, 2026. Two director nominees—Zsolt Harsanyi, Ph.D., and Barbara Lopez Kunz—were elected to terms running until the 2029 Annual Meeting. Stockholders also ratified Baker Tilly US, LLP as the company’s independent registered public accounting firm for 2026, approved the advisory "say-on-pay" vote for 2025 executive compensation, and approved the Fourth Amended and Restated 2018 Stock Incentive Plan.

Key Details

• Director elections (terms through 2029):
  • Zsolt Harsanyi, Ph.D.: For 216,997; Withheld 17,454; Broker non‑votes 402,427
  • Barbara Lopez Kunz: For 211,050; Withheld 23,401; Broker non‑votes 402,427
• Auditor ratification (2026): Baker Tilly US, LLP approved — For 606,661; Against 28,847; Abstain 1,370; Broker non‑votes 0
• Advisory vote on 2025 executive compensation: For 165,615; Against 24,031; Abstain 44,805; Broker non‑votes 402,427
• Approval of Fourth Amended and Restated 2018 Stock Incentive Plan: For 166,484; Against 64,248; Abstain 3,719; Broker non‑votes 402,427

Why It Matters
These outcomes confirm board composition and governance priorities through 2029, establish Baker Tilly as the company’s auditor for 2026, and signal stockholder support for the company’s executive pay (non‑binding) and for a refreshed stock incentive plan. For investors, the stock plan approval is material because it permits future equity awards (which can affect dilution and compensation expense), and the auditor ratification affects the firm that will review Aptevo’s 2026 financial statements.